logo-loader

UPDATE - ANGLE: Barts prostate study yields 'encouraging' results

Last updated: 16:25 11 Jun 2015 BST, First published: 07:30 11 Jun 2015 BST

prostate_cancer
Prostate cancer is the second most common form of the disease among men.
Medical devices firm ANGLE (LON:AGL) described as ‘encouraging’ early results of a study by Barts Cancer Institute, which used the former’s Parsortix device to capture and identify different types of prostate cancer cells.
 
ANGLE’s Parsortix system captures circulating tumour cells found in the blood stream.
 
In the Barts study, which assessed 44 patients with the metastatic form of the disease (where the cancer has spread) and eight with localised prostate cancer, Parsortix was 100% effective.
 
In fact it harvested a range of different cells, including the CK+, or epithelial cells, which can be captured using traditional antibody-based systems.
 
But it was also effective in isolating the CK- Vimentin+, or mesenchymal cells that play a crucial role in cancer spread.
 
Secondary cancers are the most common cause of death and cannot be captured using traditional antibody-based systems. 
 
The Barts team are taking the work a stage further and will assess whether the captured cells can be cultured in the lab.
 
If this can be done, then doctors might then be able to test in the lab the potential effectiveness of certain treatments in tackling cancer in patients. Remember patients respond differently to the drugs used to tackle the disease.
 
Researchers will also look at the molecular biomarkers in the circulating tumour cells to predict prostate cancer patient outcome and response to therapies. 
 
ANGLE chief executive Andrew Newland said: "The prospect of deployment of our repeatable, non-invasive liquid biopsy in the treatment of prostate cancer patients in therapy selection and remission monitoring is exciting.  
 
“These findings are encouraging and we look forward to further developments as soon as possible."   
 
Prostate cancer is the second most common cancer in men and the fourth most common overall. More than 1.1mln cases were recorded in 2012.
 
Broker Cenkos rates the shares a 'buy'.

Now the researchers at Barts Cancer Institute (BCI) will be expanding the work with higher numbers of patients, whilst also undertaking follow-ups of the patients studied so far, it said in a note.

"The team will also investigate the molecular biomarkers in the mesenchymal CTCs with a view to using them in both therapy selection and remission monitoring. If BCI’s work is successful there is now the potential for ANGLE to develop clinical applications for prostate cancer as well as ovarian cancer."
 
Angle shares added 2,.15% to 95p.
 

ANGLE PLC present at the Proactive One2One Investor Conference - January 11th

In a comprehensive presentation at the Proactive One2One Investor Conference, ANGLE PLC (AIM:AGL, OTCQX:ANPCY) CEO, Andrew Newland, and CFO, Ian Griffiths, detailed the company's innovative approach to cancer diagnosis and treatment. Newland emphasised ANGLE's breakthrough technology, the...

on 17/1/24